Results 21 to 30 of about 39,290 (282)

Assessment of appendix carcinoid tumors: A retrospective study

open access: yesIndian Journal of Pathology and Microbiology, 2019
Aim: This study aimed to analyze the frequency of carcinoid tumor, the applied treatments to cure it, and the survival periods of the patients thereafter in a city located in the west of Turkey, Balıkesir.
Servet Kocaoz, Gulay Turan
doaj   +1 more source

Primary carcinoid of the ovary [PDF]

open access: yesVojnosanitetski Pregled, 2011
Background. Carcinoid tumors are distinct neuroendocrine neoplasms commonly located within the gastrointestinal tract and bronchopulmonary system. The aim of this case report was to present a patient with carcinoid tumor of the ovary as a less common ...
Đurović Marina   +12 more
doaj   +1 more source

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors [PDF]

open access: yes, 2017
Background Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options.
Al‐nahhas, A   +82 more
core   +1 more source

A rare case of metastatic renal carcinoid

open access: yesBMC Urology, 2010
Background Carcinoid is an endocrine cell tumor with low-grade atypia, which is generally a low-grade malignant cancer with a good prognosis. Metastatic renal carcinoid is even rarer than primary carcinoids. Case presentation We present our experience of
Tobiume Motoi   +10 more
doaj   +1 more source

The novel mTOR inhibitor RAD001 (Everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells [PDF]

open access: yes, 2007
Background/Aim: Tumors exhibiting constitutively activated PI(3) K/Akt/mTOR signaling are hypersensitive to mTOR inhibitors such as RAD001 (everolimus) which is presently being investigated in clinical phase II trials in various tumor entities, including
Albert JM   +35 more
core   +1 more source

Primary Mesenteric Carcinoid Tumor Presenting with Carcinoid Syndrome

open access: yesCase Reports in Gastroenterology, 2018
Neuroendocrine neoplasms (NENs) are a diverse group of tumors arising throughout the body with a common origin from neuroendocrine cells. Well-differentiated NENs, also known as neuroendocrine tumors (NETs), are generally indolent and are often found ...
Oluwaseun Shogbesan   +3 more
doaj   +1 more source

Incidentally Found Rectal Carcinoid Tumor in a 46-Year-Old Female: The Potential for Complications and the Importance of Screening Guidelines

open access: yesInternational Journal of Medical Students, 2023
BACKGROUND: Carcinoid tumors are rare neuroendocrine tumors that can be found in the gastrointestinal tract as well as other areas throughout the body.
Rebecca Lapides   +3 more
doaj   +1 more source

Minute ampullary carcinoid tumor with lymph node metastases: a case report and review of literature

open access: yesWorld Journal of Surgical Oncology, 2009
Background Carcinoid tumors are usually considered to have a low degree of malignancy and show slow progression. One of the factors indicating the malignancy of these tumors is their size, and small ampullary carcinoid tumors have been sometimes treated ...
Sakano Shigeru   +9 more
doaj   +1 more source

Improving Small Lesion Segmentation in CT Scans using Intensity Distribution Supervision: Application to Small Bowel Carcinoid Tumor [PDF]

open access: yesarXiv, 2022
Finding small lesions is very challenging due to lack of noticeable features, severe class imbalance, as well as the size itself. One approach to improve small lesion segmentation is to reduce the region of interest and inspect it at a higher sensitivity rather than performing it for the entire region.
arxiv  

A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases. [PDF]

open access: yes, 2017
A challenge in precision medicine requires identification of actionable driver mutations. Critical to such effort is the deployment of sensitive and well-validated assays for mutation detection.
Ali, Siraj   +9 more
core   +1 more source

Home - About - Disclaimer - Privacy